Biotech Startup Numab Therapeutics Raises CHF 15 Series B Round
scroll south
Swiss Biotech company Numab Therapeutics has announced the closing of it's CHF 15 million Series B round from Chinese investors.
Numab Therapeutics is an oncology-focused biopharmaceutical company based in Zurich-area, Switzerland. The innovative company is writing the next chapter in cancer immunotherapy by creating multispecific antibodies that enable the pursuit of novel therapeutic strategies.To foster the venture's growth, the startup closed a CHF 15 million series B investment round and signed a new partnership with the Chinese company and investor group Sunshine Guojian.
Numab Therapeutics ranked among the most promising Swiss-based startups at the TOP 100 Swiss Startup Award in 2013 and 2014.
Numab Therapeutics AG: Innovates and develops antibody-based therapeutics
Our proprietary platforms Lambda-Cap™ and MATCH™ are designed to create differentiated therapeutics on a repeatable basis. Using a novel, rational process, our discovery and engineering technology yie... Read more
